Login to Your Account

Biogen Idec's Daclizumab Looking Good in Phase IIb

By Catherine Shaffer

Wednesday, August 10, 2011
New Phase IIb results showed that Biogen Idec Inc.'s multiple sclerosis (MS) candidate, daclizumab high-yield process (DAC HYP), reduced the annualized relapse rate significantly compared to placebo and reduced disability progression by as much as 57 percent. Those results make DAC HYP potentially competitive with Tysabri (natalizumab), Lemtrada (alemtuzumab) and Gilenya (fingolimod). However, safety signals from the trial, including two deaths, may limit market potential for the drug.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription